Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…Certara2026 年 2 月 13 日
Pediatric drug development: From “wild west” to model-informed confidence Blog Pediatric drug development: From “wild west” to model-informed confidence Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…Certara2026 年 2 月 11 日
Why Many Global Drugs Never Reach Japan Press Coverage Why Many Global Drugs Never Reach Japan Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…Certara2026 年 2 月 5 日
Trial designs: Non-inferiority vs. superiority vs. equivalence BlogKnowledge Base Trial designs: Non-inferiority vs. superiority vs. equivalence Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…Matt Zierhut, PhD MBA2026 年 2 月 3 日
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants Publication Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…Certara2026 年 2 月 2 日
Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®) On-Demand Webinar Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®) Discover population PK modeling made faster and easier with Phoenix NLME and Pirana in this…Certara2026 年 1 月 30 日
Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®) On-Demand Webinar Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®) This on demand session demonstrates how Phoenix WinNonlin® and other tools work together within Phoenix®…Certara2026 年 1 月 27 日
How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most Blog How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…Certara2026 年 1 月 26 日
Milliliters, Milligrams, and Moles: Keeping Up with Units in NCA Webinar Milliliters, Milligrams, and Moles: Keeping Up with Units in NCA Danielle Pillsbury2026 年 1 月 22 日